Journal of Thrombosis and Thrombolysis

, Volume 34, Issue 4, pp 552–561

Antithrombotic therapy in heparin-induced thrombocytopenia: guidelines translated for the clinician

  • Connie N. Hess
  • Richard C. Becker
  • John H. Alexander
  • Renato D. Lopes
Article

Abstract

Heparin-induced thrombocytopenia (HIT) is a clinicopathologic syndrome initiated by heparin exposure and characterized by thrombocytopenia and paradoxical thrombophilia. HIT is mediated by the formation of antibodies against the platelet factor 4/heparin complex, which leads to platelet activation, thrombin generation, and potentially fatal thrombotic sequelae. The clinical presentation of HIT is variable and can be easily overlooked. Although a number of functional and antigen-based immunoassays have been developed to detect the presence of HIT antibodies, initial diagnosis is often based on recognition of thrombocytopenia in the appropriate clinical context and later confirmed with immunologic testing. Given the serious clinical consequences of HIT, immediate cessation of heparin products and administration of non-heparin anticoagulants are crucial components of treatment. We provide a review of the clinical syndrome and practical summary of treatment recommendations from the most recent 2012 American College of Chest Physicians evidence-based guidelines for the treatment and prevention of HIT.

Keywords

Heparin-induced thrombocytopenia Thrombosis Antithrombotic therapy Guidelines 

References

  1. 1.
    Natelson EA, Lynch EC, Alfrey CP Jr, Gross JB (1969) Heparin-induced thrombocytopenia. An unexpected response to treatment of consumption coagulopathy. Ann Intern Med 71:1121–1125PubMedGoogle Scholar
  2. 2.
    Jang IK, Hursting MJ (2005) When heparins promote thrombosis: review of heparin-induced thrombocytopenia. Circulation 111:2671–2683. doi:10.1161/CIRCULATIONAHA.104.518563 PubMedCrossRefGoogle Scholar
  3. 3.
    Chong BH (2003) Heparin-induced thrombocytopenia. J Thromb Haemost 1:1471–1478PubMedCrossRefGoogle Scholar
  4. 4.
    Warkentin TE, Greinacher A, Koster A, Lincoff AM (2008) Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 133:340S–380S. doi:10.1378/chest.08-0677 PubMedCrossRefGoogle Scholar
  5. 5.
    Warkentin TE (2004) An overview of the heparin-induced thrombocytopenia syndrome. Semin Thromb Hemost 30:273–283. doi:10.1055/s-2004-831039 PubMedCrossRefGoogle Scholar
  6. 6.
    Arepally GM, Ortel TL (2006) Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 355:809–817. doi:10.1056/NEJMcp052967 PubMedCrossRefGoogle Scholar
  7. 7.
    Lindhoff-Last E, Eichler P, Stein M, Plagemann J, Gerdsen F, Wagner R, Ehrly AM, Bauersachs R (2000) A prospective study on the incidence and clinical relevance of heparin-induced antibodies in patients after vascular surgery. Thromb Res 97:387–393PubMedCrossRefGoogle Scholar
  8. 8.
    Foo SY, Everett BM, Yeh RW, Criss D, Laposata M, Van Cott EM, Jang IK (2006) Prevalence of heparin-induced thrombocytopenia in patients undergoing cardiac catheterization. Am Heart J 152(290):e291–e297. doi:10.1016/j.ahj.2006.04.028 Google Scholar
  9. 9.
    Lopes RD, Ohman EM, Granger CB, Honeycutt EF, Anstrom KJ, Berger PB, Crespo EM, Oliveira GB, Moll S, Moliterno DJ, Abrams CS, Becker RC (2009) Six-month follow-up of patients with in-hospital thrombocytopenia during heparin-based anticoagulation [from the Complications After Thrombocytopenia Caused by Heparin (CATCH) registry]. Am J Cardiol 104:1285–1291. doi:10.1016/j.amjcard.2009.06.045 PubMedCrossRefGoogle Scholar
  10. 10.
    Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S, Crowther M (2012) Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e495S–e530S. doi:10.1378/chest.11-2303 PubMedCrossRefGoogle Scholar
  11. 11.
    Martel N, Lee J, Wells PS (2005) Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 106:2710–2715. doi:10.1182/blood-2005-04-1546 PubMedCrossRefGoogle Scholar
  12. 12.
    Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG (1995) Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 332:1330–1335. doi:10.1056/NEJM199505183322003 PubMedCrossRefGoogle Scholar
  13. 13.
    Harbrecht U, Bastians B, Kredteck A, Hanfland P, Klockgether T, Pohl C (2004) Heparin-induced thrombocytopenia in neurologic disease treated with unfractionated heparin. Neurology 62:657–659PubMedCrossRefGoogle Scholar
  14. 14.
    Girolami B, Prandoni P, Stefani PM, Tanduo C, Sabbion P, Eichler P, Ramon R, Baggio G, Fabris F, Girolami A (2003) The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood 101:2955–2959. doi:10.1182/blood-2002-07-2201 PubMedCrossRefGoogle Scholar
  15. 15.
    Smythe MA, Koerber JM, Mattson JC (2007) The incidence of recognized heparin-induced thrombocytopenia in a large, tertiary care teaching hospital. Chest 131:1644–1649. doi:10.1378/chest.06-2109 PubMedCrossRefGoogle Scholar
  16. 16.
    Warkentin TE, Sheppard JA, Sigouin CS, Kohlmann T, Eichler P, Greinacher A (2006) Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood 108:2937–2941. doi:10.1182/blood-2005-11-012450 PubMedCrossRefGoogle Scholar
  17. 17.
    Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG (2000) Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 96:1703–1708PubMedGoogle Scholar
  18. 18.
    Francis JL, Palmer GJ 3rd, Moroose R, Drexler A (2003) Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery. Ann Thorac Surg 75:17–22PubMedCrossRefGoogle Scholar
  19. 19.
    Ban-Hoefen M, Francis C (2009) Heparin induced thrombocytopenia and thrombosis in a tertiary care hospital. Thromb Res 124:189–192. doi:10.1016/j.thromres.2009.01.006 PubMedCrossRefGoogle Scholar
  20. 20.
    Warkentin TE, Kelton JG (2001) Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 344:1286–1292. doi:10.1056/NEJM200104263441704 PubMedCrossRefGoogle Scholar
  21. 21.
    Warkentin TE (1998) Clinical presentation of heparin-induced thrombocytopenia. Semin Hematol 35:9–16PubMedGoogle Scholar
  22. 22.
    Warkentin TE, Makris M, Jay RM, Kelton JG (2008) A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia. AmJ Med 121:632–636. doi:10.1016/j.amjmed.2008.03.012 CrossRefGoogle Scholar
  23. 23.
    Rice L, Attisha WK, Drexler A, Francis JL (2002) Delayed-onset heparin-induced thrombocytopenia. Ann Intern Med 136:210–215PubMedGoogle Scholar
  24. 24.
    Greinacher A, Farner B, Kroll H, Kohlmann T, Warkentin TE, Eichler P (2005) Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost 94:132–135. doi:10.1267/THRO05010132 PubMedGoogle Scholar
  25. 25.
    Lubenow N, Warkentin TE, Greinacher A, Wessel A, Sloane DA, Krahn EL, Magnani HN (2006) Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and/or coumarin explain the rapid shift in clinical practice during the 1990s. Thromb Res 117:507–515. doi:10.1016/j.thromres.2005.04.011 PubMedCrossRefGoogle Scholar
  26. 26.
    Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM, Bartholomew J, Sham R, Lerner RG, Zeigler ZR, Rustagi PK, Jang IK, Rifkin SD, Moran J, Hursting MJ, Kelton JG (2001) Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 103:1838–1843PubMedCrossRefGoogle Scholar
  27. 27.
    Wallis DE, Workman DL, Lewis BE, Steen L, Pifarre R, Moran JF (1999) Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 106:629–635PubMedCrossRefGoogle Scholar
  28. 28.
    Hong AP, Cook DJ, Sigouin CS, Warkentin TE (2003) Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. Blood 101:3049–3051. doi:10.1182/blood-2002-05-1448 PubMedCrossRefGoogle Scholar
  29. 29.
    Warkentin TE, Greinacher A (2003) Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg 76:638–648PubMedCrossRefGoogle Scholar
  30. 30.
    Gruel Y, Pouplard C, Nguyen P, Borg JY, Derlon A, Juhan-Vague I, Regnault V, Samama M (2003) Biological and clinical features of low-molecular-weight heparin-induced thrombocytopenia. Br J Haematol 121:786–792PubMedCrossRefGoogle Scholar
  31. 31.
    Warkentin TE, Roberts RS, Hirsh J, Kelton JG (2005) Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study. Chest 127:1857–1861. doi:10.1378/chest.127.5.1857 PubMedCrossRefGoogle Scholar
  32. 32.
    Tardy B, Tardy-Poncet B, Fournel P, Venet C, Jospe R, Dacosta A (1999) Lower limb veins should be systematically explored in patients with isolated heparin-induced thrombocytopenia. Thromb Haemost 82:1199–1200PubMedGoogle Scholar
  33. 33.
    Warkentin TE (2002) Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia. Arch Pathol Lab Med 126:1415–1423. doi:10.1043/0003-9985(2002)126<1415:PCMALT>2.0.CO;2 PubMedGoogle Scholar
  34. 34.
    ten Berg MJ, van den Bemt PM, Huisman A, Schobben AF, Egberts TC, van Solinge WW (2009) Compliance with platelet count monitoring recommendations and management of possible heparin-induced thrombocytopenia in hospitalized patients receiving low-molecular-weight heparin. Ann Pharmacother 43:1405–1412. doi:10.1345/aph.1L646 PubMedCrossRefGoogle Scholar
  35. 35.
    Rogers BA, Cowie AS (2010) The monitoring of heparin induced thrombocytopenia following surgery: an audit and international survey. J Perioper Pract 20:66–69PubMedGoogle Scholar
  36. 36.
    Denys B, Stove V, Philippe J, Devreese K (2008) A clinical-laboratory approach contributing to a rapid and reliable diagnosis of heparin-induced thrombocytopenia. Thromb Res 123:137–145. doi:10.1016/j.thromres.2008.04.020 PubMedCrossRefGoogle Scholar
  37. 37.
    Bryant A, Low J, Austin S, Joseph JE (2008) Timely diagnosis and management of heparin-induced thrombocytopenia in a frequent request, low incidence single centre using clinical 4T’s score and particle gel immunoassay. Br J Haematol 143:721–726. doi:10.1111/j.1365-2141.2008.07401.x PubMedCrossRefGoogle Scholar
  38. 38.
    Warkentin TE, Linkins LA (2010) Non-necrotizing heparin-induced skin lesions and the 4T’s score. J Thromb Haemost 8:1483–1485. doi:10.1111/j.1538-7836.2010.03880.x PubMedCrossRefGoogle Scholar
  39. 39.
    Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A (2006) Evaluation of pretest clinical score (4 T’s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 4:759–765. doi:10.1111/j.1538-7836.2006.01787.x PubMedCrossRefGoogle Scholar
  40. 40.
    Napolitano LM, Warkentin TE, Almahameed A, Nasraway SA (2006) Heparin-induced thrombocytopenia in the critical care setting: diagnosis and management. Crit Care Med 34:2898–2911. doi:10.1097/01.CCM.0000248723.18068.90 PubMedCrossRefGoogle Scholar
  41. 41.
    Chong BH, Burgess J, Ismail F (1993) The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost 69:344–350PubMedGoogle Scholar
  42. 42.
    Bakchoul T, Giptner A, Najaoui A, Bein G, Santoso S, Sachs UJ (2009) Prospective evaluation of PF4/heparin immunoassays for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 7:1260–1265. doi:10.1111/j.1538-7836.2009.03465.x PubMedCrossRefGoogle Scholar
  43. 43.
    Warkentin TE, Sheppard JI, Moore JC, Sigouin CS, Kelton JG (2008) Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost 6:1304–1312. doi:10.1111/j.1538-7836.2008.03025.x PubMedCrossRefGoogle Scholar
  44. 44.
    Altuntas F, Matevosyan K, Burner J, Shen YM, Sarode R (2008) Higher optical density of an antigen assay predicts thrombosis in patients with heparin-induced thrombocytopenia. EurJ Haematol 80:429–435. doi:10.1111/j.1600-0609.2008.01035.x CrossRefGoogle Scholar
  45. 45.
    Zwicker JI, Uhl L, Huang WY, Shaz BH, Bauer KA (2004) Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost 2:2133–2137. doi:10.1111/j.1538-7836.2004.01039.x PubMedCrossRefGoogle Scholar
  46. 46.
    Ramacciotti E, Wahi R, Messmore HL (2008) Contaminated heparin preparations, severe adverse events and the contact system. Clin Appl Thromb Hemost 14:489–491. doi:10.1177/1076029608324291 PubMedCrossRefGoogle Scholar
  47. 47.
    Hoppensteadt DA, Wahi R, Adiguzel C, Iqbal O, Ramacciotti E, Bick RL, Messmore HL, Bansal V, Fareed J (2008) Contaminant in the recalled unfractionated heparin preparations: where is the problem? Clin Appl Thromb Hemost 14:261–266. doi:10.1177/1076029608317932 PubMedCrossRefGoogle Scholar
  48. 48.
    Kishimoto TK, Viswanathan K, Ganguly T, Elankumaran S, Smith S, Pelzer K, Lansing JC, Sriranganathan N, Zhao G, Galcheva-Gargova Z, Al-Hakim A, Bailey GS, Fraser B, Roy S, Rogers-Cotrone T, Buhse L, Whary M, Fox J, Nasr M, Dal Pan GJ, Shriver Z, Langer RS, Venkataraman G, Austen KF, Woodcock J, Sasisekharan R (2008) Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 358:2457–2467. doi:10.1056/NEJMoa0803200 PubMedCrossRefGoogle Scholar
  49. 49.
    Guerrini M, Beccati D, Shriver Z, Naggi A, Viswanathan K, Bisio A, Capila I, Lansing JC, Guglieri S, Fraser B, Al-Hakim A, Gunay NS, Zhang Z, Robinson L, Buhse L, Nasr M, Woodcock J, Langer R, Venkataraman G, Linhardt RJ, Casu B, Torri G, Sasisekharan R (2008) Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol 26:669–675. doi:10.1038/nbt1407 PubMedCrossRefGoogle Scholar
  50. 50.
    Pan J, Qian Y, Zhou X, Pazandak A, Frazier SB, Weiser P, Lu H, Zhang L (2010) Oversulfated chondroitin sulfate is not the sole contaminant in heparin. Nat Biotechnol 28:203–207. doi:10.1038/nbt0310-203 author reply 207-211PubMedCrossRefGoogle Scholar
  51. 51.
    Yi Q, Jing P, Xiaodong Z, Weiser P, Hong L, Shih FF, Porche-Sorbet R, Eby C, Lijuan Z (2010) Heparin and oversulfated heparin byproduct induce thrombin generation through contact system activation in plasma of patients with HIT. Clin Appl Thromb Hemost 16:251–260. doi:10.1177/1076029610362072 CrossRefGoogle Scholar
  52. 52.
    Greinacher A (2009) Heparin-induced thrombocytopenia. J Thromb Haemost 7:9–12. doi:10.1111/j.1538-7836.2009.03385.x PubMedCrossRefGoogle Scholar
  53. 53.
    Suvarna S, Espinasse B, Qi R, Lubica R, Poncz M, Cines DB, Wiesner MR, Arepally GM (2007) Determinants of PF4/heparin immunogenicity. Blood 110:4253–4260. doi:10.1182/blood-2007-08-105098 PubMedCrossRefGoogle Scholar
  54. 54.
    Greinacher A, Potzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt C (1994) Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 71:247–251PubMedGoogle Scholar
  55. 55.
    Warkentin TE, Kelton JG (1996) A 14-year study of heparin-induced thrombocytopenia. Am J Med 101:502–507PubMedCrossRefGoogle Scholar
  56. 56.
    Babcock RB, Dumper CW, Scharfman WB (1976) Heparin-induced immune thrombocytopenia. N Engl J Med 295:237–241. doi:10.1056/NEJM197607292950501 PubMedCrossRefGoogle Scholar
  57. 57.
    Warkentin TE, Elavathil LJ, Hayward CP, Johnston MA, Russett JI, Kelton JG (1997) The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 127:804–812PubMedGoogle Scholar
  58. 58.
    Hursting MJ, Lewis BE, Macfarlane DE (2005) Transitioning from argatroban to warfarin therapy in patients with heparin-induced thrombocytopenia. Clin Appl Thromb Hemost 11:279–287PubMedCrossRefGoogle Scholar
  59. 59.
    Koster A, Dyke CM, Aldea G, Smedira NG, McCarthy HL II, Aronson S, Hetzer R, Avery E, Spiess B, Lincoff AM (2007) Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. Ann Thorac Surg 83:572–577. doi:10.1016/j.athoracsur.2006.09.038 PubMedCrossRefGoogle Scholar
  60. 60.
    Dyke CM, Aldea G, Koster A, Smedira N, Avery E, Aronson S, Spiess BD, Lincoff AM (2007) Off-pump coronary artery bypass with bivalirudin for patients with heparin-induced thrombocytopenia or antiplatelet factor four/heparin antibodies. Ann Thorac Surg 84:836–839. doi:10.1016/j.athoracsur.2007.04.007 PubMedCrossRefGoogle Scholar
  61. 61.
    Lee MS, Liao H, Yang T, Dhoot J, Tobis J, Fonarow G, Mahmud E (2011) Comparison of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing an invasive strategy: a meta-analysis of randomized clinical trials. Int J Cardiol 152:369–374. doi:10.1016/j.ijcard.2010.08.007 PubMedCrossRefGoogle Scholar
  62. 62.
    Mahaffey KW, Lewis BE, Wildermann NM, Berkowitz SD, Oliverio RM, Turco MA, Shalev Y, Ver Lee P, Traverse JH, Rodriguez AR, Ohman EM, Harrington RA, Califf RM (2003) The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. J Invasive Cardiol 15:611–616PubMedGoogle Scholar
  63. 63.
    Lewis BE, Matthai WH Jr, Cohen M, Moses JW, Hursting MJ, Leya F (2002) Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Intervent 57:177–184. doi:10.1002/ccd.10276 CrossRefGoogle Scholar
  64. 64.
    Cochran K, DeMartini TJ, Lewis BE, J OB, Steen LH, Grassman ED, Leya F (2003) Use of lepirudin during percutaneous vascular interventions in patients with heparin-induced thrombocytopenia. J Invasive Cardiol 15:617–621PubMedGoogle Scholar
  65. 65.
    Jolicoeur EM, Wang T, Lopes RD, Ohman EM (2007) Percutaneous coronary interventions in patients with heparin-induced thrombocytopenia. Curr Cardiol Rep 9:396–405PubMedCrossRefGoogle Scholar
  66. 66.
    Lubenow N, Kempf R, Eichner A, Eichler P, Carlsson LE, Greinacher A (2002) Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. Chest 122:37–42PubMedCrossRefGoogle Scholar
  67. 67.
    Mehta R, Golichowski A (2004) Treatment of heparin induced thrombocytopenia and thrombosis during the first trimester of pregnancy. J Thromb Haemost 2:1665–1666. doi:10.1111/j.1538-7836.2004.00883.x PubMedCrossRefGoogle Scholar
  68. 68.
    Chapman ML, Martinez-Borges AR, Mertz HL (2008) Lepirudin for treatment of acute thrombosis during pregnancy. Obstet Gynecol 112:432–433. doi:10.1097/AOG.0b013e31817788e0 PubMedCrossRefGoogle Scholar
  69. 69.
    Gerhardt A, Zotz RB, Stockschlaeder M, Scharf RE (2007) Fondaparinux is an effective alternative anticoagulant in pregnant women with high risk of venous thromboembolism and intolerance to low-molecular-weight heparins and heparinoids. Thromb Haemost 97:496–497PubMedGoogle Scholar
  70. 70.
    Mazzolai L, Hohlfeld P, Spertini F, Hayoz D, Schapira M, Duchosal MA (2006) Fondaparinux is a safe alternative in case of heparin intolerance during pregnancy. Blood 108:1569–1570. doi:10.1182/blood-2006-03-009548 PubMedCrossRefGoogle Scholar
  71. 71.
    Link A, Girndt M, Selejan S, Mathes A, Bohm M, Rensing H (2009) Argatroban for anticoagulation in continuous renal replacement therapy. Crit Care Med 37:105–110. doi:10.1097/CCM.0b013e3181932394 PubMedCrossRefGoogle Scholar
  72. 72.
    Polkinghorne KR, McMahon LP, Becker GJ (2002) Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients. Am J Kidney Dis 40:990–995. doi:10.1053/ajkd.2002.36331 PubMedCrossRefGoogle Scholar
  73. 73.
    Henny CP, ten Cate H, Surachno S, Stevens P, Buller HR, den Hartog M, ten Cate JW (1985) The effectiveness of a low molecular weight heparinoid in chronic intermittent haemodialysis. Thromb Haemost 54:460–462PubMedGoogle Scholar
  74. 74.
    Shantsila E, Lip GY, Chong BH (2009) Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management. Chest 135:1651–1664. doi:10.1378/chest.08-2830 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Connie N. Hess
    • 1
  • Richard C. Becker
    • 1
  • John H. Alexander
    • 1
  • Renato D. Lopes
    • 1
  1. 1.Duke Clinical Research Institute, Duke University Medical CenterDurhamUSA

Personalised recommendations